![Yang Sheng Lin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Yang Sheng Lin is currently General Manager, Director & Chief Researcher at Tripartite Therapeutics, Inc. since 2015.
Formerly, Dr. Lin was Chief Scientific Officer at Medigen Biotechnology Corp.
from 2012 to 2014.
Education includes a doctorate from Harvard University.
| Companies | Position | Start |
|---|---|---|
| TRIPARTITE THERAPEUTICS INC. | Director/Board Member | 01/08/2015 |
| Companies | Position | End |
|---|---|---|
| MEDIGEN BIOTECHNOLOGY CORP. | Chief Tech/Sci/R&D Officer | - |
Active
Inactive
Listed companies
Private companies
| Private companies | 3 |
|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Medigen Biotechnology Corp.
 Medigen Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Develops and produces biopharmaceutical products | Health Technology |
Hanyang Biotechnology Ltd.
 Hanyang Biotechnology Ltd. Pharmaceuticals: MajorHealth Technology Develops drugs and antibody-drug conjugate therapies for cancer | Health Technology |
Select your edition
All financial news and data tailored to specific country editions
Choose MarketScreener 
